Stockscreener 앱 받기
1.305
3.16%
0.045
전일 마감가:
$1.26
열려 있는:
$1.27
하루 거래량:
39,819
Relative Volume:
0.22
시가총액:
$3.21M
수익:
-
순이익/손실:
$-15.08M
주가수익비율:
-0.2033
EPS:
-6.42
순현금흐름:
$-11.56M
1주 성능:
+10.15%
1개월 성능:
+7.42%
6개월 성능:
-73.51%
1년 성능:
-88.67%
1일 변동 폭
$1.26
$1.3286
1주일 범위
$1.19
$1.34
52주 변동 폭
$1.01
$11.82
엔버릭 바이오 Stock (ENVB) Company Profile
명칭
Enveric Biosciences Inc
전화
239-302-1707
주소
4851 TAMIAMI TRAIL N, SUITE 200, NAPLES
ENVB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENVB
Enveric Biosciences Inc
|
1.30 | 2.99M | 0 | -15.08M | -11.56M | -6.42 |
|
ONC
Beone Medicines Ltd Adr
|
256.46 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.79 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2213 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.34 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
499.45 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
엔버릭 바이오 주식(ENVB)의 최신 뉴스
Enveric Receives U.S. Patent for Sleep, CNS Therapeutics - Insider Monkey
Enveric’s Patent Win Targets New Frontiers in Sleep Medicine - microdose.buzz
Enveric Biosciences Holds 2025 Annual Stockholders Meeting - TipRanks
Enveric Biosciences (ENVB) Secures Patent for Novel CNS Therapeu - GuruFocus
Enveric Biosciences Receives New US Patent on Molecules for Central Nervous System, Sleep Therapeutics - marketscreener.com
Enveric Biosciences secures patent for sleep disorder molecules By Investing.com - Investing.com Nigeria
Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds | ENVB Stock News - GuruFocus
Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds - Yahoo Finance
Enveric Biosciences announces results from EB-003 trial - Yahoo Finance
Enveric’s EB-003 shows statistically significant improvements in model of severe chronic depression - BioWorld MedTech
Enveric Biosciences Reports Positive Preclinical Results For Lead Drug Candidate EB-003 - marketscreener.com
Enveric Biosciences reports breakthrough in depression model By Investing.com - Investing.com India
Enveric Biosciences (ENVB) Reports Promising Preclinical Results - GuruFocus
Enveric Biosciences reports breakthrough in depression model - Investing.com Australia
Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003 | ENVB Stock News - GuruFocus
Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003 - Business Wire
Enveric Biosciences (NASDAQ:ENVB) Stock Price Down 0.8% – Here’s Why - Defense World
Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease - marketscreener.com
Enveric Biosciences Stakes Its Claim in Neurodegeneration Market - microdose.buzz
Enveric Biosciences files provisional patent for new molecules By Investing.com - Investing.com Canada
Enveric Biosciences Identifies Neuroplastogen Candidates with Po - GuruFocus
Enveric Biosciences (ENVB) Explores New Path with Neurodegenerative Drug Patent | ENVB Stock News - GuruFocus
Enveric Biosciences files new provisional patent application - TipRanks
Enveric Biosciences (ENVB) Explores New Path with Neurodegenerat - GuruFocus
Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results - BioSpace
Enveric Biosciences Reports First Quarter 2025 Financial and Cor - GuruFocus
Enveric Biosciences (ENVB) Projected to Post Earnings on Tuesday - Defense World
Enveric Biosciences stock plummets after pricing $5M capital raise - MSN
Enveric Biosciences (NASDAQ:ENVB) Trading Down 1% – Here’s Why - Defense World
Enveric Biosciences appoints new accounting firm - Investing.com India
Enveric Biosciences appoints new accounting firm By Investing.com - Investing.com South Africa
ENVB Stock Touches 52-Week Low at $1.12 Amid Market Challenges - Investing.com Canada
ENVB Stock Touches 52-Week Low at $1.12 Amid Market Challenges By Investing.com - Investing.com South Africa
Psychedelic: Enveric, Filament Health report earnings results - TipRanks
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024 - BioSpace
Enveric posts $9.5M loss for 2024, but revenue could be on horizon with licensing deals - Green Market Report
Enveric Lands Massive $184M Biotech Licensing Deals as EB-003 Shows Promise - Stock Titan
Enveric Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Enveric Biosciences, Inc. SEC 10-K Report - TradingView
Enveric Biosciences Inc. (ENVB) reports earnings - qz.com
Enveric Biosciences Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Enveric Biosciences Announces 1-for-15 Reverse Stock Split - MSN
Enveric Biosciences Participating in BIO-Europe Spring® - The Bakersfield Californian
Enveric Biosciences (ENVB) to Release Quarterly Earnings on Monday - Defense World
What is HC Wainwright’s Forecast for ENVB Q4 Earnings? - The AM Reporter
Q4 Earnings Forecast for ENVB Issued By HC Wainwright - Defense World
HC Wainwright Reiterates “Buy” Rating for Enveric Biosciences (NASDAQ:ENVB) - Defense World
Enveric Biosciences, Inc. (ENVB) Seeks Buyers for PsyAI Trademark Amid Shift to Neuroplastogen Development - Insider Monkey
Enveric Biosciences launches RFP solicitation process for PsyAI trademark - Yahoo Finance
Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark - 01Net
Enveric Biosciences Says Regains Compliance With Nasdaq Bid Price Rule -March 06, 2025 at 11:30 am EST - Marketscreener.com
엔버릭 바이오 (ENVB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.30%
3.35%
자본화:
|
볼륨(24시간):